Steris Q2 FY2027 Results: Net Income $214 Million on Revenue of $1.59 Billion
- US stocks
- Earnings
- Health Care

Steris (NYSE: STE) reported GAAP revenue of $1.59 billion and GAAP net income attributable to shareholders of $213.7 million for its fiscal 2027 second quarter, it said on 4 Nov 2026. Diluted EPS was $2.19 on a GAAP basis, and adjusted EPS, a company-defined measure, was $2.94 per diluted share.
Key highlights
- Revenue (GAAP): $1.59 billion, up 8.8% YoY and 6.4% QoQ
- Net income (GAAP): $213.7 million, up 11.4% YoY and 6.8% QoQ
- Adjusted EPS (company-defined): $2.94 per diluted share
- Free cash flow, six months (company-defined): $492.5 million
Summary
| Particulars | Q2 FY2027 | Q2 FY2026 | YoY | Q1 FY2027 | QoQ |
|---|---|---|---|---|---|
| Revenue | 1,588.6 | 1,460.3 | +8.8% | 1,492.7 | +6.4% |
| 294.3 | 265.8 | +10.7% | 285.8 | +3.0% | |
| Operating margin | 18.53% | 18.20% | +0.33 pp | 19.15% | -0.62 pp |
| 213.7 | 191.9 | +11.4% | 200.1 | +6.8% | |
| Net income margin | 13.45% | 13.14% | +0.31 pp | 13.41% | +0.04 pp |
| Diluted EPS ($) | 2.19 | 1.94 | +12.9% | n/a | n/a |
Figures are in $ million except EPS; YoY compares with Q2 FY2026 and QoQ with Q1 FY2027. Q2 FY2027 is the three months to 30 Sep 2026, from the company's release. Earlier quarters are checked against the company's SEC XBRL filings. GAAP; net income attributable to the company; diluted EPS. Changes and margins computed by Blacklitt.
Against the second quarter of fiscal 2026, revenue rose 8.8% and operating income rose 10.7%. Net income was 13.5% of revenue, against 13.1% a year earlier, and operating margin was 18.5%, against 18.2%. Against the first quarter of fiscal 2027, revenue rose 6.4% and net income rose 6.8%.
Adjusted figures exclude amortization and restructuring
Adjusted net income, a company-defined measure, was $286.8 million, or $2.94 per diluted share, against $244.5 million, or $2.47 per diluted share, a year earlier. The company said its adjusted figures exclude amortization of acquired intangible assets, acquisition and integration charges, tax restructuring costs and restructuring charges, among other items.
The company said the pre-tax impact of tariff refunds on its as reported results was a benefit of approximately $20 million in the quarter.
Healthcare and Life Sciences drove segment growth
Healthcare revenue was $1.12 billion, up 9% as reported, and its operating income was $269.2 million, against $259.5 million a year earlier. The company said that increase was primarily due to improved volume and price, partially offset by inflation, lower productivity and investments.
Life Sciences revenue was $170.6 million, up 18%, with operating income of $75.8 million, against $59.9 million. The company said this reflects improvement in price, productivity, volume and favorable mix. Applied Sterilization Technologies revenue was $295.6 million, up 5%.
Outlook raised on adjusted EPS
The company now expects fiscal 2027 adjusted EPS of $11.35 to $11.55, up from $11.10 to $11.30, and said the revised outlook includes about $0.18 from tariff refunds received year-to-date. Its revenue growth outlook is unchanged, at 7-8% as reported and 6-7% constant currency organic.
The company approved a separate restructuring plan during the quarter, with total charges of approximately $45 million, about $25 million of them in the second quarter, and annualized savings of about $9 million.
For the six months, net cash provided by operations was $656.1 million, against $707.8 million, and free cash flow, a company-defined measure, was $492.5 million, against $527.7 million. The company said the decline was driven primarily by a significantly lower contribution from working capital, partially offset by higher net income.
Inference
Diluted shares averaged 97.6 million in the quarter, against 98.8 million a year earlier, and cash dividends declared were $0.69 per share, against $0.63. Over the six months the company repurchased ordinary shares for $215.9 million, against $111.1 million a year earlier.
The release does not give a dividend payment date or the second-quarter share repurchase amount alone.
Filed with the US SEC on . Reference: Original filing (SEC)
Disclaimer:
The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.
Figures are from the company's filings with the US Securities and Exchange Commission and are in US dollars. Investing in US stocks from India is subject to the Liberalised Remittance Scheme, currency risk and taxes in both countries.

